TY  - JOUR
AU  - Drosten, Matthias
AU  - Barbacid, Mariano
PY  - 2020
DO  - 10.1016/j.ccell.2020.03.013
SN  - 1535-6108
UR  - http://hdl.handle.net/20.500.12105/14770
AB  - KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we...
LA  - eng
PB  - Cell Press
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Humans
KW  - Mitogen-Activated Protein Kinases
KW  - Neoplasms
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins p21(ras)
TI  - Targeting the MAPK Pathway in KRAS-Driven Tumors.
TY  - journal article
ER  -